Objective: Chemokine 12, C-X-C Motif Chemokine Ligand 12 (CXCL12), and its receptor C-X-C Motif Chemokine Ligand 4 (CXCR4), both play essential and critical roles in the development of different types of cancers. Almost, in all of the cancers, overexpression of these two chemokines is a key to diagnose of cancers and lead them to progress, an increment in proliferation, the invasive feature of different cell lines, metastasis, and a noticeable decrement in apoptosis. Although the impact of this axis on cancer development is known and investigated, there was no review article about this molecular pathway and the drug effects on this cascade is not written. In this regard, we probed the researches about this intracellular process and the drugs that are useful for suppressing it on one-by-one cancer.
Materials and Methods: We reviewed this study with scientific keywords in ScienceDirect, Google Scholar, and PubMed. Our research process was to review every study that has looked at this process in every cancer, as well as the drugs selected to treat cancer from 14 years ago onwards.
Results: Our researches showed that there are some inhibitors that are introduced in order to block the pathway in many cancers. In addition, the data related to the effect of this pathway on some types of cancers are not enough.
Conclusions: Summing up, the present study clears a route to suppress the invasion of cancers and bold the tips that have not been worked on yet.
To cite this article
CXCL12-CXCR4 axis: its role and the drug inhibitors on each type of cancers
Submission date: 07 Dec 2021
Revised on: 09 Feb 2022
Accepted on: 17 Jun 2022
Published online: 19 Jul 2022
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.